Yüklüyor......
Randomized Phase II Designs
As the use of molecularly targeted agents, which are anticipated to increase overall and progression-free survival (OS and PFS), but not necessarily tumor response, has increased in oncology, there has been a corresponding increase in the recommendation and use of randomized phase II designs. Such d...
Kaydedildi:
| Asıl Yazarlar: | , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2009
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3774021/ https://ncbi.nlm.nih.gov/pubmed/19276275 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-2031 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|